{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:37:10Z","timestamp":1726418230568},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.04.001","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T12:53:19Z","timestamp":1308919999000},"page":"313-321","source":"Crossref","is-referenced-by-count":1,"title":["Perspective of clinical research in follicular NHL: Interaction between science and industry"],"prefix":"10.1016","volume":"24","author":[{"given":"Gregg","family":"Fine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Horning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2011.04.001_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab as single first line therapy for patients with follicular lymphoma and a low tumor burden; clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2011.04.001_bib2","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent NHL","volume":"20","author":"Hainsworth","year":"2002","journal-title":"JCO"},{"issue":"15","key":"10.1016\/j.beha.2011.04.001_bib3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.beha.2011.04.001_bib4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German low-grade lymphoma study group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2011.04.001_bib5","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"JCO"},{"issue":"13","key":"10.1016\/j.beha.2011.04.001_bib6","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.04.001_bib7","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-Term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different Schedules in trial SAKK 35\/98","author":"Martinelli","year":"2010","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.beha.2011.04.001_bib9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine and prednisone prolongs progression-free survival in advanced indolent lymphoma; results of the randomized phase III ECOG 1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"JCO"},{"key":"10.1016\/j.beha.2011.04.001_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 randomised controlled trial","volume":"377","author":"Salles","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2011.04.001_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hec.1454","article-title":"Spending on new drug development","volume":"19","author":"Adams","year":"2010","journal-title":"Health Econ"},{"key":"10.1016\/j.beha.2011.04.001_bib12","unstructured":"Kulynych, J. Will the FDA relinquish the \u201cgold standard\u201d for new drug approval? Redefining \u201csubstantial evidence\u201d in the FDA Modernization Act of 1997. Accessed http:\/\/www.fdli.org\/pubs\/journal%20online\/54_1\/art12.pdf."},{"issue":"28","key":"10.1016\/j.beha.2011.04.001_bib13","first-page":"1","article-title":"ODAC says clear clinical benefit required when sponsors claim progression delay","volume":"35","author":"Goldberg","year":"2009","journal-title":"Cancer Lett"},{"year":"2010","series-title":"Letter from the FDA","author":"Woodcock","key":"10.1016\/j.beha.2011.04.001_bib14"},{"issue":"2","key":"10.1016\/j.beha.2011.04.001_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.beha.2011.04.001_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy I patients with rituximab-refractory indolent B-cell non-Hodgkin lymphoma","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.beha.2011.04.001_bib17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Oafumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.beha.2011.04.001_bib18","first-page":"430","article-title":"Inotuzumab Ozogamicin (CMC-544) in patients with indolent B-cell NHL that is refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy: preliminary safety and efficacy from a phase 2 trail","volume":"116","author":"Goy","year":"2010","journal-title":"ASH Annu Meet Abstr"},{"issue":"Suppl. 18","key":"10.1016\/j.beha.2011.04.001_bib19","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/jco.2007.25.18_suppl.3582","article-title":"A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer","volume":"25","author":"Camidge","year":"2007","journal-title":"JCO"},{"key":"10.1016\/j.beha.2011.04.001_bib20","article-title":"Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL)","volume":"15","author":"Belada","year":"2010","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.beha.2011.04.001_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA\u2019s accelerated approval process","volume":"24","author":"Fleming","year":"2005","journal-title":"Health Aff"},{"key":"10.1016\/j.beha.2011.04.001_bib22","first-page":"947","article-title":"Surrogate end points in cancer research: a critique. cancer epidemiology","volume":"5","author":"Schatzkin","year":"1996","journal-title":"Biomarkers Prev"},{"issue":"9","key":"10.1016\/j.beha.2011.04.001_bib23","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radichemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German low-grade lymphoma study group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.04.001_bib24","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","article-title":"High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS","volume":"105","author":"Deconinck","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.04.001_bib25","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","article-title":"Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA)","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2011.04.001_bib26","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","article-title":"Prospective, multicenter randomized GITMO\/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib27","first-page":"2754","article-title":"Role of different frontline regimens in achieving complete response in follicular lymphoma: a meta-analysis of CR rate and its relation to hazard rate for disease progression","volume":"108","author":"Saville","year":"2006","journal-title":"Blood (ASH Annu Meet Abstracts)"},{"issue":"32","key":"10.1016\/j.beha.2011.04.001_bib28","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with Yttrium-90-Ibritumomab tituxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"JCO"},{"key":"10.1016\/j.beha.2011.04.001_bib29","first-page":"428","article-title":"A phase 2, double-Blind, Placebo-controlled trial of rituximab + galiximab vs rituximab + Placebo in advanced follicular non-Hodgkin\u2019s lymphoma (NHL)","volume":"116","author":"Bence-Bruckler","year":"2010","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2011.04.001_bib30","first-page":"768","article-title":"Final results of a randomized phase 2 multicenter study of two bortezomib Schedules in patients with recurrent or refractory follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) study FL-05","volume":"116","author":"Ribrag","year":"2010","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2011.04.001_bib31","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International Workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.04.001_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.04.001_bib33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of Positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"JCO"},{"key":"10.1016\/j.beha.2011.04.001_bib34","article-title":"Result of FDG PET-CT imaging after immunochemotherapy induction is a powerful and independent prognostic indicator of outcome for patients with Follicular Lymphoma: an analysis from the PRIMA study","volume":"116","author":"Trotman","year":"2010","journal-title":"Blood (ASH Annu Meet Abstracts)"},{"key":"10.1016\/j.beha.2011.04.001_bib35","article-title":"The mystery of FDG-PET aviditiy in follicular lymphoma. Does microenvironment play the key role?","volume":"116","author":"Janikova","year":"2010","journal-title":"Blood (ASH Annu Meet Abstracts)"},{"issue":"4","key":"10.1016\/j.beha.2011.04.001_bib36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","article-title":"Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma","volume":"7","author":"Zinzani","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.beha.2011.04.001_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","article-title":"Value of [18F]Fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?","volume":"8","author":"Janikova","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.beha.2011.04.001_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdq024","article-title":"PDG-GET in the assessment of patients with follicular lymphoma treated by ibrituomab titxetan Y 90: multicentric study","author":"Lopci","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.04.001_bib39","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.bjc.6602040","article-title":"Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients","volume":"91","author":"Zinani","year":"2004","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.beha.2011.04.001_bib40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET with fluorine-18fluorodeoxyglucose ([18F]FDG)) after first-line chemotherapy in non-Hodgkin\u2019s lymphoma; is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.beha.2011.04.001_bib41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bbmt.2008.11.026","article-title":"Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on mid-treatment FDG-PET scanning","volume":"15","author":"Kassamon","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.04.001_bib43","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","article-title":"PET after two to three cycles of chemotherapy predicts progression-free and overall serviva in high-stage non-Hodgkin lymphoma","volume":"16","author":"Mikhaeel","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.04.001_bib44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MNM.0b013e3282f813a4","article-title":"Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET","volume":"29","author":"Berkowitz","year":"2008","journal-title":"Nuc Med Comm"},{"key":"10.1016\/j.beha.2011.04.001_bib45","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198711053171904","article-title":"Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas","volume":"317","author":"Weiss","year":"1987","journal-title":"NEJM"},{"key":"10.1016\/j.beha.2011.04.001_bib46","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood.V82.8.2510.2510","article-title":"Translocation (14;18) positive cells are present in the circulation of the majority of patients with localized (\u2217stage I and II) follicular non-Hodgkin\u2019s lymphoma","volume":"82","author":"Lambrechts","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib47","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1200\/JCO.1993.11.7.1344","article-title":"Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advance stage follicular lymphoma","volume":"11","author":"Berinstein","year":"1993","journal-title":"JCO"},{"key":"10.1016\/j.beha.2011.04.001_bib48","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","article-title":"All advanced stage non-Hodgkin\u2019s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment","volume":"78","author":"Gribben","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","article-title":"BCL-2 family: regulators of cell death","volume":"16","author":"Chao","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.beha.2011.04.001_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.beha.2004.08.019","article-title":"What is remission in follicular lymphoma and what is its relevance","volume":"18","author":"Buckstein","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2011.04.001_bib51","first-page":"S14","article-title":"Bcl-2 clearance: optimizing outcomes in follicular non-Hodgkin\u2019s lymphoma","volume":"29","author":"Berinstein","year":"2002","journal-title":"BMT"},{"issue":"4","key":"10.1016\/j.beha.2011.04.001_bib52","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2353\/jmoldx.2007.070038","article-title":"\u201cMinor\u201d BCL2 breakpoints in follicular lymphoma","volume":"9","author":"Weinberg","year":"2007","journal-title":"J Mol Diag"},{"key":"10.1016\/j.beha.2011.04.001_bib53","first-page":"2497","article-title":"High molecular response rate and clinical correlation in patients with follicular lymphoma treated with cyclophosphamide-vincristine-prednisone plus interferon alpha 2b","volume":"9","author":"Fernandez-Ruiz","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2011.04.001_bib54","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib55","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib56","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood.V81.12.3449.3449","article-title":"Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma","volume":"81","author":"Gribben","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib57","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3324\/haematol.12253","article-title":"A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin\u2019s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy","volume":"93","author":"Bishton","year":"2008","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.beha.2011.04.001_bib58","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/10428190902927005","article-title":"The persistence of t(14:18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for \u2018a lymphoma stem cell\u2019","volume":"50","author":"Janikova","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.beha.2011.04.001_bib59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2008.07101.x","article-title":"Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients","volume":"141","author":"Hirt","year":"2008","journal-title":"BJH"},{"issue":"9","key":"10.1016\/j.beha.2011.04.001_bib60","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","article-title":"Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response an long-term outcome in follicular non-Hodgkin lymphoma","volume":"105","author":"Rambaldi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.04.001_bib61","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.leukres.2006.01.014","article-title":"One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2\/IgH positive cells: is the end of molecular monitoring near?","volume":"30","author":"Schmitt","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2011.04.001_bib62","article-title":"Moffitt, Merck join forces","author":"Varian","year":"2006","journal-title":"St Petersburg Times"},{"key":"10.1016\/j.beha.2011.04.001_bib63","article-title":"Sharing of data leads to progress on Alzheimer\u2019s","author":"Kolata","year":"2010","journal-title":"NYT"},{"key":"10.1016\/j.beha.2011.04.001_bib64","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Designa and standardization of o PCR primers and protocols for detectiono of clonal immunoglobulin and T-cell receptor gene recombination in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.04.001_bib65","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0002-9440(10)64905-X","article-title":"High frequeny of t(14;18)-translocation breakpoints outside of major breakipoint and minor cluster regions in follicular lymphomas","volume":"160","author":"Albinger-Hegyi","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beha.2011.04.001_bib66","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/sj.leu.2402568","article-title":"Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features; specific subtypes or same disease?","volume":"16","author":"Buchonnet","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.04.001_bib67","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3324\/haematol.11172","article-title":"An International study to standardize the detection and quanitiation of BCR-ABL transcripts from stablized peripheral blood preparations by quantitative PCR","volume":"92","author":"Muller","year":"2007","journal-title":"Hematological"},{"key":"10.1016\/j.beha.2011.04.001_bib68","first-page":"115","article-title":"Detecting adverse events using information technology","volume":"10","author":"Bates","year":"2003","journal-title":"JAMIA"},{"key":"10.1016\/j.beha.2011.04.001_bib69","first-page":"731","article-title":"Using electronic medical redcords to enhance detection and reporting of vaccine adverse events","volume":"14","author":"Hinrichsen","year":"2007","journal-title":"JAMIA"},{"key":"10.1016\/j.beha.2011.04.001_bib70","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1001\/archinte.165.19.2272","article-title":"Effect of a clinical trial alert system on physician participation in trial recruitment","volume":"165","author":"Embi","year":"2005","journal-title":"Arch Int Med"},{"issue":"4","key":"10.1016\/j.beha.2011.04.001_bib71","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11606-007-0449-0","article-title":"Comparison of electronic physician prompts versus waitroom case-finding on clinical trial enrollment","volume":"23","author":"Rollman","year":"2003","journal-title":"JGIM"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T23:46:00Z","timestamp":1712533560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000375"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.04.001","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}